<DOC>
	<DOCNO>NCT00179751</DOCNO>
	<brief_summary>Phase I determine MDT evaluate safety profile oral lenalidomide day 1-21 weekly gemcitabine day 1 , 8 , &amp; 15 28 day cycle Phase II explore anti-tumor activity safety combination subject advance pancreatic carcinoma . Subjects receive oral lenalidomide day 1-21 weekly gemcitabine day 1 , 8 , &amp; 15 28 day cycle document disease progression occur .</brief_summary>
	<brief_title>A Phase I/II Study Lenalidomide Combination With Gemcitabine Patients With Untreated Advanced Carcinoma Pancreas</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<criteria>1 . Subjects must understand voluntarily sign informed consent document . 2 . Age &gt; = 18 year time signing informed consent form . 3 . Subjects must able adhere study visit schedule protocol requirement . 4 . Histological documentation advance pancreatic carcinoma amenable curative surgery definitive radiation . 5 . Radiographic clinical evidence measurable advanced pancreatic carcinoma . Subjects must measurable disease least 2 cm diameter . 6 . Subjects may previously treat radiation therapy 5fluorouracil radiosensitizer adjuvant set currently evidence progression . 7 . ECOG performance status 0 1 ( Appendix I : ECOG Performance Status Scale ) . 8 . Women childbearing potential ( WCBP ) must negative serum urine pregnancy test within 7 day start study drug . In addition , sexually active WCBP must agree use adequate contraceptive method ( oral , injectable , implantable hormonal contraceptive ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; vasectomized partner ) study medication . 1 . Any following laboratory abnormality : 1 . Absolute neutrophil count ( ANC ) &lt; 1,500 cells/mm3 ( 1.5 x 109/L ) 2 . Platelet count &lt; 100,000 cells/mm3 ( 100 x 109/L ) 3 . Serum creatinine &gt; 2.5 mg/dL ( 221 mmol/L ) 4 . Serum SGOT/AST SGPT/ALT &gt; 3.0 x upper limit normal ( ULN ) 5 . Serum total bilirubin &gt; 2.0 mg/dL ( 34 mmol/L ) 2 . Any serious medical condition psychiatric illness place subject unacceptable risk study participation would prevent subject signing informed consent . 3 . Prior history malignancy ( except basal cell squamous cell carcinoma carcinoma situ breast ) unless subject free disease &gt; = 1 year . 4 . Known brain leptomeningeal disease ( CT scan MRI brain required case clinical suspicion central nervous system involvement ) . 5 . Prior use systemic therapy treatment carcinoma pancreas exception 5fluorouracil radiosensitizer adjuvant setting . 6 . Concurrent use anticancer agent . 7 . Any prior use lenalidomide . 8 . Prior &gt; = grade 3 ( see Appendix III ) allergic reaction/hypersensitivity thalidomide . 9 . Prior &gt; = grade 3 ( see Appendix III ) rash desquamating ( blister ) rash take thalidomide . 10 . Use standard/experimental anticancer drug therapy within 28 day initiation study drug therapy . 11 . Pregnant lactating female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2005</verification_date>
	<keyword>cc-5013</keyword>
	<keyword>revlimid</keyword>
	<keyword>pancreatic cancer</keyword>
</DOC>